Compared with AS alone, coexisting ATTR-CA was associated with an increased risk of mortality (HR 1.3, 95% CI 1.1-1.4) in a ...

Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Barclays analyst initiates Positive coverage on Anteris Technologies, forecasting a 4%-5% U.S. TAVR market share for DurAVR ...

The following is a summary of “Computed tomography derived predictors of left ventricular obstruction after TAVR,” published ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Lipoprotein(a) doesn’t influence calcification or outcomes in TAVR, shifting focus to other AS progression factors.

THE SOLVE-TAVI trial demonstrated that both valve type and anaesthesia strategy yielded comparable long-term outcomes in ...

Nat Clin Pract Cardiovasc Med. 2008;5(12):764-765. We believe that strategies to avoid or reduce the severity of PPM should be individualized and take into account multiple variables, such as ...